Zacks Investment Research upgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a buy rating in a report released on Friday. Zacks Investment Research currently has $14.00 target price on the stock.
According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
Other equities analysts also recently issued research reports about the company. BidaskClub downgraded Oxford Immunotec Global from a hold rating to a sell rating in a research report on Thursday, January 11th. Cowen reiterated a buy rating and set a $15.00 price objective on shares of Oxford Immunotec Global in a research report on Monday, January 22nd. BTIG Research set a $21.00 price objective on Oxford Immunotec Global and gave the stock a buy rating in a research report on Monday, December 18th. Finally, ValuEngine downgraded Oxford Immunotec Global from a sell rating to a strong sell rating in a research report on Thursday, March 1st. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $17.80.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.02. Oxford Immunotec Global had a negative return on equity of 42.38% and a negative net margin of 31.90%. The firm had revenue of $25.03 million for the quarter, compared to the consensus estimate of $25.12 million. During the same quarter last year, the business posted ($0.22) earnings per share. The firm’s revenue was up 5.6% compared to the same quarter last year. analysts forecast that Oxford Immunotec Global will post -0.9 EPS for the current year.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction on Friday, February 16th. The stock was sold at an average price of $12.01, for a total value of $36,030.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 8.11% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of OXFD. Consonance Capital Management LP purchased a new stake in Oxford Immunotec Global in the fourth quarter valued at $15,645,000. Perceptive Advisors LLC raised its position in Oxford Immunotec Global by 955.1% in the third quarter. Perceptive Advisors LLC now owns 465,356 shares of the company’s stock valued at $7,818,000 after purchasing an additional 421,250 shares during the period. Alyeska Investment Group L.P. raised its position in Oxford Immunotec Global by 44.0% in the third quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock valued at $22,773,000 after purchasing an additional 413,904 shares during the period. Redmile Group LLC raised its position in Oxford Immunotec Global by 13.0% in the fourth quarter. Redmile Group LLC now owns 2,318,387 shares of the company’s stock valued at $32,388,000 after purchasing an additional 266,900 shares during the period. Finally, RTW Investments LP raised its position in Oxford Immunotec Global by 21.9% in the third quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock valued at $17,344,000 after purchasing an additional 185,453 shares during the period. Institutional investors own 93.31% of the company’s stock.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.